Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986202 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose | EXPERIMENTAL | BMS-986202 or Placebo specified dose on specified days |
| Part B: Multiple Ascending Dose | EXPERIMENTAL | BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days |
| Part C: Multiple Ascending Dose-Japanese descent | EXPERIMENTAL | BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent |
| Part D: Relative Bioavailability | EXPERIMENTAL | BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days |
| Part E: Proof of Mechanism | EXPERIMENTAL | BMS-986202 or Placebo + Ustekinumab specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| BMS-986202 | DRUG | - |
| Placebo | DRUG | - |
| Interferon alpha-2a recombinant | DRUG | - |
| Famotidine | DRUG | - |
| Ustekinumab | DRUG | - |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy Male and Female participants * 18 to 50 years of age (Parts A-D) * 18 to 70 years of age (Part E) * Diagnosed with plaque psoriasis (Part E) Exclusi...
BMS-986202 is an investigational small molecule being developed for the treatment of psoriasis, a dermatological condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety and potential efficacy in treating this condition.
BMS-986202 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the stock exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and potential efficacy of this investigational drug for the treatment of psoriasis.
BMS-986202 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and potential efficacy. The drug is being studied for the treatment of psoriasis.
BMS-986202 has been studied in a Phase 1 clinical trial with the identifier NCT02763969, titled "Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis." This trial, which has been completed, enrolled 357 participants and was conducted in Australia. The study included healthy volunteers and individuals with psoriasis.
BMS-986202 is a unique investigational drug candidate developed by Bristol-Myers Squibb. It is not known to be the same as any other marketed drug. It is being studied as a potential treatment for psoriasis and is currently in Phase 1 clinical development.